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Abstract
Background: Insulin-like growth factor-I (IGF-I) exerts neuroprotective actions in the central nervous system that
are mediated at least in part by control of activation of astrocytes. In this study we have assessed the efficacy of
exogenous IGF-I and IGF-I gene therapy in reducing the inflammatory response of astrocytes from cerebral cortex.
Methods: An adenoviral vector harboring the rat IGF-I gene and a control adenoviral vector harboring a hybrid
gene encoding the herpes simplex virus type 1 thymidine kinase fused to Aequorea victoria enhanced green
fluorescent protein were used in this study. Primary astrocytes from mice cerebral cortex were incubated for 24 h
or 72 h with vehicle, IGF-I, the IGF-I adenoviral vector, or control vector; and exposed to bacterial
lipopolysaccharide to induce an inflammatory response. IGF-I levels were measured by radioimmunoassay. Levels of
interleukin 6, tumor necrosis factor-a, interleukin-1b and toll-like receptor 4 mRNA were assessed by quantitative
real-time polymerase chain reaction. Levels of IGF-I receptor and IGF binding proteins 2 and 3 were assessed by
western blotting. The subcellular distribution of nuclear factor B (p65) was assessed by immunocytochemistry.
Statistical significance was assessed by one way analysis of variance followed by the Bonferroni pot hoc test.
Results: IGF-I gene therapy increased IGF-I levels without affecting IGF-I receptors or IGF binding proteins.
Exogenous IGF-I, and IGF-I gene therapy, decreased expression of toll-like receptor 4 and counteracted the
lipopolysaccharide-induced inflammatory response of astrocytes. In addition, IGF-I gene therapy decreased
lipopolysaccharide-induced translocation of nuclear factor B (p65) to the cell nucleus.
Conclusion: These findings demonstrate efficacy of exogenous IGF-I and of IGF-I gene therapy in reducing the
inflammatory response of astrocytes. IGF-I gene therapy may represent a new approach to reduce inflammatory
reactions in glial cells.
Background
As a source of growth factors and of immunologically
relevant cytokines and chemokines, astrocytes play a
pivotal role in the pathophysiology of neurodegenerative
diseases [1-3] and in the type and extent of central ner-
vous system immune and inflammatory responses [4].
These responses may promote tissue repair and contri-
bute to recovery of homeostasis under acute neurode-
gerative conditions. However, sustained inflammatory
responses of astrocytes in chronic neurodegenerative dis-
eases may enhance tissue damage through amplification
of brain inflammation and consequent neuronal injury
[4-8]. Therefore, to limit neuronal cell death under
chronic neurodegenerative conditions, it is important to
develop tools to control brain inflammatory reactions.
IGF-I is locally produced in the nervous system and it
is also actively transported to the brain from plasma
through the choroid plexus [9,10]. IGF-I has pleiotropic
actions in nervous tissue, influencing neuronal develop-
ment, synaptic plasticity, neuroendocrine regulation,
adult neurogenesis and cognition [11-14]. IGF-I is also a
potent neuroprotective molecule [10,13,15,16] exerting
this function in part by reducing brain inflammation
[17,18] and reactive astrocytosis [19]. In response to
neurodegenerative conditions, astrocytes express IGF-I,
probably as an endogenous neuroprotective and
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anti-inflammatory mechanism [20-23]. Consequently,
the development of methodologies to increase IGF-I
production by glial cells is a logical approach to imple-
ment anti-inflammatory IGF-I-based therapeutic strate-
gies for neurodegenerative diseases.
We have recently constructed a recombinant adeno-
virus vector harboring the rat IGF-I gene [24,25]. Using
this vector we have shown efficacy of IGF-I gene ther-
apy to increase IGF-I levels in cerebrospinal fluid and to
reduce neuronal damage in vivo [24,25]. In the present
study we have explored whether exogenous IGF-I and
IGF-I gene therapy regulate the inflammatory response
of astrocytes.
Methods
Adenoviral vectors
A recombinant adenovirus (RAd) vector harboring the
rat IGF-I gene (RAd-IGF-I) was constructed as pre-
viously described [24] using a variant of the two-plasmid
method [26] The cDNA coding for the rat IGF-I gene
(kindly donated by Dr. Peter Rotwein, Department of
Biochemistry and Molecular Biology, Oregon Health &
Science University, Portland, OR), obtained from the
mRNA for the IGF-Ib precursor form [27], was placed
under the control of the mCMV promoter in order
to construct the genome of the desired RAd-IGF-I
(Figure 1). The newly generated RAd was rescued from
human embryo kidney 293 (HEK293) cell lysates and
plaque purified. It was further purified by ultracentrifu-
gation in a CsCl gradient. Final virus stocks were
titrated by a serial dilution plaque assay.
A control RAd vector (RAd-TK/GFP) harboring a
hybrid gene encoding the herpes simplex virus type 1
(HSV-1) thymidine kinase fused to Aequorea victoria
enhanced green fluorescent protein (a kind gift from Dr.
Jacques Galipeau, McGill University, Montreal, Canada)
was constructed following the general procedures out-
lined above (Figure 1). The corresponding gene product,
fusion protein TK/GFP, emits green fluorescence with
high intensity when excited with 470-nm wideband light
[28]. This hybrid gene is also driven by the mCMV pro-
moter. The vector was expanded in 293 cells and puri-
fied and titrated as indicated above.
Astrocyte cultures
Astrocyte cultures were prepared by mechanical disso-
ciation of cerebral cortex from newborn CD1 mice
[29]. Experimental procedures were approved by our
Institutional Animal Use and Care Committee (Spanish
National Research Council Animal Experimentation
Committee). Cell culture reagents were purchased
from Invitrogen (Paisley, UK). The cortex was isolated
under a dissecting microscope and cleaned of choroid
plexus and meninges. Cell suspensions were filtered
through a 70-μm nylon cell strainer into phenol
red free Dulbecco’s modified Eagle medium (DMEM)
containing 10% fetal calf serum and 1% penicillin-
streptomycin. After centrifugation, cells were cultured
in 75-cm2 tissue culture flasks at 37°C and 5% CO2.
The medium was changed after 4 days in culture and
subsequently two times a week for the entire culture
period. Cellular confluence was observed 10 days after
plating, producing around 4.3 × 106 cells per flask,
showing a polygonal flat morphology. Enriched astro-
cyte cultures (90-95% of GFAP immunoreactive cells)
were obtained after overnight shaking at 37°C a
280 rpm in a table top shaker (Thermo Forma, Mar-
ietta, OH) to minimize oligodendrocyte and microglia
contamination. Astrocytes were removed from the
flasks by incubation with 0.25% trypsin (type II-S;
Sigma-Aldrich, St Louis, MO) and 0.04% EDTA
(Sigma) and plated onto poly-L-lysine-coated six-well
plates or coverslips in medium supplemented with 10%
FBS. Cells were plated at 15,000 cells/cm2 for immu-
nocytochemistry and at 30,000 cells/cm2 for gene
expression or protein assays.
Cell treatments
One day after seeding, culture medium was changed
using serum free medium and the cells were treated for
24 or 72 h with vehicle or IGF-I (50 or 100 nM), and in
a second experiment the cells were treated for 24 or 72
h with RAd-IGF-I, RAd-TK/GFP or medium alone
(uninfected control cells). The efficacy of infection,
assessed with the RAd-TK/GFP vector, was approxi-
mately 60% of the cells in the culture. Some cultures
were incubated with lipopolysaccharide (LPS, from
Escherichia coli 026:B6, Sigma; 500 ng/ml) to induce an
inflammatory response [30]. LPS was added for 1 h to
determine NFB subcellular localization and for 5 h to
assess IGF-I receptor and IGF binding proteins by wes-
tern blotting, and interleukin 6 (IL6), tumor necrosis
factor-a (TNF-a), interleukin-1b (IL-1b) and toll-like
receptor 4 (TLR4) mRNA levels by quantitative real-
time polymerase chain reaction. In some experiments,
astrocytes were incubated with the IGF-I receptor tyro-
sine kinase inhibitor picropodophyllin (PPP, Calbio-
chem, 100 ng/ml) or vehicle.
Figure 1 Schematic representation of the construction of the
RAd-IGF-I and RAd-TK/GFP adenoviral vectors. PmCMV, mouse
cytomegalovirus promoter; IGF-I, cDNA for rat IGF-1; TK/GFP, hybrid
DNA sequence encoding the fusion protein TK/GFP; ITR, inverted
terminal repeat; ΔE1 and ΔE3, deletions in the AD5 genome; SV40,
simian virus 40 polyadenylation signal; Ψ, packaging signal.
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IGF-I assay
IGF-I was extracted from supernatants by acid-ethanol
cryoprecipitation after incubation for 24 h with RAd-
TK/GFP, RAd-IGF-I or medium alone. IGF-I levels were
assessed by radioimmunoassay as previously described
[24] using antibody UB2-495 (distributed by A. F. Par-
low, NHPP, NIDDK). Recombinant human IGF-I (Cell
Sciences Inc., Canton, MA, USA) was used as tracer and
unlabeled ligand.
Analysis of gene expression by quantitative real-time
polymerase chain reaction (q-PCR)
Interleukin 6 (IL6), tumor necrosis factor-a (TNF-a),
interleukin-1b (IL-1b) and toll-like receptor 4 (TLR4)
mRNA levels were assessed by quantitative real-time
polymerase chain reaction. Cells were lysed and total
RNA was extracted using an illustra RNAspin Mini
RNA Isolation Kit (GE Healthcare, Buckinghamshire,
UK). First strand cDNA was prepared from RNA using
an RevertAidTM H Minus First Strand cDNA Synthesis
Kit (MBI Fermentas, Bath, UK) following the manufac-
turer’s instructions. After reverse transcription (RT), the
cDNA was diluted 1:4 and 5 μl were amplified by real-
time PCR in 20 μl using SYBR Green master mix or
TaqMan Universal PCR Master Mix (Applied Biosys-
tems, AB, Foster City, CA) in a ABI Prism 7500
Sequence Detector (AB), with conventional AB cycling
parameters (40 cycles of 95°C, 15 s; 60°C, 1 min). Primer
sequences were designed using Primer Express (AB) and
were as follows: for IL6, forward, 5’-GAAACCGCTATG
AAGTTCCTCTCTG-3’ and reverse, 5’-TGTTGGGAG
TGGTATCCTCTGTGA-3’; for TNF-a, forward 5’-
GAAAAGCAAGCAGCCAACCA-3’ and reverse, 5’-CG
GATCATGCTTTCTGTGCTC-3’; for IL-1b, forward
5’- CGACAAAATACCTGTGGCCT-3’ and reverse, 5’-
TTCTTTGGGTATTGCTTGGG-3’; and for TLR4, for-
ward 5’-GGCTCCTGGCTAGGACTCTGA-3’ and
reverse, 5’-TCTGATCCATGCATTGGTAGGT-3’. Gly-
ceraldehyde-3-phosphate dehydrogenase (GAPDH) was
selected as control housekeeping gene. GADPH TaqMan
probes and primers were the Assay-on-Demand gene
expression products (AB). After amplification, a dena-
turing curve was performed to ensure the presence of
unique amplification products. All reactions were per-
formed in triplicate. IL6, TNF-a, IL-1b and TLR4 gene
expressions were normalized to GAPDH.
Western blotting
For western blotting analysis, medium and the cells were
homogenized in 200 μl of lysis buffer (150 mM NaCl,
20 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 1 mg/ml
aprotinin, 1 mg/ml leupeptin, and 1 mg/ml phenyl-
methylsulfonyl fluoride). Protein concentrations were
determined using a Bio-Rad protein assay (Bio-Rad
Laboratories, Hercules, CA). Electrophoresis of 25-μg
protein extracts was performed on a 10% acrylamide
SDS-PAGE gel and immunoblotted onto nitrocelulose
membranes. Membranes were incubated for 1 h in TBST
(10 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.1% Tween-
20) containing 5% wt/vol nonfat dry milk, and then
incubated overnight with the primary antibodies. The
following antibodies were used: anti-insulin-like growth
factor-binding protein-2 (IGFBP-2; Millipore Iberica,
Madrid, Spain; diluted 1/2000), anti-IGFBP-3 (H-98;
Santa Cruz Biotechnology, Santa Cruz, CA; diluted 1/
1000) and anti-IGF-I receptor-b (IGF-IRb; C-20, Santa
Cruz Biotechnology, Santa Cruz, CA; 1/1000). Immunor-
eactivity was detected with horseradish peroxidase-conju-
gated goat anti-rabbit or anti-mouse antibodies (Jackson
ImmunoResearch Europe, Newmarket, Suffolk, UK;
Diluted 1:10000) and enhanced chemiluminescence
(Amersham Pharmacia Biotech, Essex, UK). Band intensi-
ties were quantified using Quantity One 1-D Analysis
Software (Bio-Rad Laboratories, Inc., Hercules, CA).
Immunocytochemistry
Subcellular distribution of NFB (p65) was assessed by
immunocytochemistry after incubation for 24 h with
RAd-IGF-I or RAd-TK/GFP and for 1 h with LPS or
vehicle. Cells were fixed for 15 min at room tempera-
ture in 4% paraformaldehyde, permeabilized for 15 min
with 0.3% Triton X-100 in PBS and incubated for
15 min with 10% normal goat serum in PBS, to block
unspecific binding of the secondary antibody. Cells were
then incubated for 1 h with anti-NFB (p65) mouse
monoclonal antibody (BD Biosciences, diluted 1:50 in
PBS with 1% BSA). After washing in PBS, cells were
incubated with goat anti-mouse Alexa-fluor 594 (Invi-
trogen, diluted 1:1,000). Cell nuclei were stained with
DAPI.
Statistical analysis
Statistical significance was assessed by one-way or two-
way analysis of variance (ANOVA) followed by the Bon-
ferroni post hoc test using GraphPad Prism 5 (GraphPad
Software, San Diego, CA) or by Student’s t-test when
only two groups were compared. A probability of P <
0.05 was adopted for statistical significance. Data shown
in the figures are the results of four independent experi-
ments. Data are represented as mean ± SEM.
Results
IGF-I increases the expression of IL6, IL-1b and TNF-a and
decreases the expression of toll-like receptor 4 (TLR4) in
astrocytes under basal conditions
mRNA levels of IL6, IL-1b and TNF-a were assessed in
astrocytes 24 h after the addition of IGF-I (50 and
100 nM) to the cultures. IGF-I, at a concentration of
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50 nM, resulted in a significant increase in mRNA levels
for IL6, IL-1b and TNF-a compared to astrocytes trea-
ted only with vehicle (Figure 2). In contrast, 100 nM
IGF-I did not significantly affect IL6, IL-1b and TNF-a
mRNA levels (Figure 2). The increase in IL-1b mRNA
levels was still detected 72 h after addition of 50 nM
IGF-I to the cultures (Figure 2). However, levels of IL6
and TNF-a were not significantly different between
astrocytes treated with IGF-I or vehicle, 72 h after addi-
tion of IGF-I (Figure 2).
Figure 2 IGF-I increases the expression of IL6, IL-1b and TNF-a and decreases the expression of TLR4 in astrocytes under basal
conditions. mRNA levels of IL6 (A,B), IL-1b (C,D), TNF-a (E,F) and TLR4 (G,H) in astrocytes 24 h (A,C,E,G) or 72 h (B,D,F,H) after the addition of
IGF-I (50 or 100 nM) or vehicle to the cultures. Data are presented as mean ± SEM and are expressed as percentage of control (vehicle) values. *,
**,***, Significant differences (* P < 0.05; **P < 0.01; ***P < 0.001) in comparison to the values of cultures treated with vehicle only. §§, §§§,
Significant differences (§§P < 0.01; §§§P < 0.001) between 50 nM and 100 nM IGF-I.
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TLR4 mRNA levels were significantly decreased in
cultures treated with IGF-I at either 50 nM or 100 nM,
compared to cultures treated with vehicle. The effect
of IGF-I on TLR4 levels was still detected 72 h after
treatment (Figure 2).
IGF-I exerts an anti-inflammatory action on LPS-treated
astrocytes
To determine whether IGF-I affects the response of
astrocytes to a proinflammatory challenge, we first
assessed mRNA levels of IL6, TNF-a, IL-1b and TLR4
in primary astrocyte cultures incubated with LPS (500
ng/ml) or vehicle. Treatment with LPS resulted in a
marked increase in mRNA levels of IL6, IL-1b and
TNF-a (Figure 3). In contrast, TLR4 mRNA levels were
not affected by LPS (Figure 3).
For LPS-treated astrocytes, mRNA levels of IL6, IL-1b
and TLR4 were significantly decreased 24 h after admin-
istration of 50 or 100 nM IGF-I in comparison to cul-
tures treated with LPS alone (Figure 4). mRNA levels of
IL6, IL-1b and TLR4 returned to control levels 72 h
after addition of 50 nM IGF-I to the cultures (Figure 4).
RAd-IGF-I increases IGF-I levels in astrocyte cultures
Having established the effects of exogenous application of
IGF-I to astrocytes on IL6, IL-1b, TNF-a and TLR4
mRNA levels under basal and LPS-stimulated conditions,
we investigated whether similar effects could be obtained
by increasing endogenous expression of IGF-I in these
cells using an adenoviral vector. To assess the efficacy of
IGF-I gene transfer, IGF-I levels were assessed in the cul-
ture medium after incubation of the astrocytes for 24 h
with RAd-IGF-I, RAd-TK/GFP, or medium alone (unin-
fected cells; Figure 5). IGF-I levels were significantly
higher in the medium of astrocytes incubated with RAd-
IGF-I compared to that of astrocytes incubated with
RAd-TK/GFP or with medium alone (Figure 5). In con-
trast IGF-I receptor levels and IGFBP2 levels were not
significantly different in astrocytes incubated for 24 h
with RAd-IGF-I, RAd-TK/GFP, or medium alone (data
not shown). IGFBP3 was undetectable in the cultures.
RAd-IGF-I increases expression of IL6 and IL-1b and
decreases expression of TLR4 under basal conditions
IL6 and IL-1b mRNA levels in astrocytes were significantly
increased 24 h after incubation of cultures with RAd-IGF-
I, compared to those of uninfected astrocytes or to astro-
cytes treated with RAd-TK/GFP (Figure 6). In contrast, 72
h after incubation of the cultures with RAd-TK/GFP,
astrocytes showed a significant increase in mRNA levels of
IL6 and IL-1b, compared to uninfected astrocytes or to
astrocytes treated with RAd-IGF-I (Figure 6). IL6 and IL-
1b mRNA levels 72 h after incubation with RAd-IGF-I
Figure 3 LPS increases expression of IL6, IL-1b, TNF-a and
TLR4 in astrocytes. mRNA levels of IL6 (A), IL-1b (B), TNF-a (C) and
TLR4 (D) in astrocytes treated for 5 h with LPS (500 ng/ml) or
vehicle only. Data are presented as mean ± SEM and are expressed
as percentage of control (vehicle) values. **,***, Significant
differences (**P < 0.01; ***P < 0.001) in comparison to the values of
cultures treated with vehicle.
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were not significantly different from those in uninfected
astrocytes (Figure 6). TNF-a mRNA levels were increased
72 h after incubation with RAd-IGF-I. TLR4 mRNA levels
were significantly decreased 24 h after incubation of the
cultures with RAd-IGF-I, compared to astrocytes treated
with RAd-TK/GFP (Figure 6).
RAd-IGF-I exerts an anti-inflammatory action on LPS-
treated astrocytes
After LPS treatment, astrocytes incubated with RAd-
IGF-I showed a significant decrease in mRNA levels for
IL6, IL-1b and TNF-a compared to astrocytes incubated
with RAd-TK/GFP (Figure 7). In addition, IL6 and IL-
1b mRNA levels were significantly decreased in cultures
incubated with RAd-IGF-I compared to uninfected cul-
tures. In LPS-treated astrocytes, TLR4 mRNA levels
were significantly decreased in cultures incubated for 24
h or 72 h with RAd-IGF-I compared to astrocytes trea-
ted with RAd-TK/GFP. In addition, TLR4 mRNA levels
were significantly decreased in astrocytes incubated with
RAd-IGF-I for 24 h compared to uninfected astrocytes.
Role of IGF-I receptor in the effects of RAd-IGF-I
To determine whether the effects of RAd-IGF-I on IL6,
IL-1b, TNF-a and TLR4 mRNA levels are mediated by
IGF-I receptor, astrocyte cultures were treated with the
IGF-I receptor antagonist cyclolignan picropodophyllin
(PPP). As shown in figure 8, PPP did not block the
Figure 4 IGF-I decreases the inflammatory response of astrocytes exposed to LPS. mRNA levels of IL6 (A,B), IL-1b (C,D), TNF-a (E,F) and
TLR4 (G,H) in astrocytes 24 h (A,C,E,G) or 72 h (B,D,F,H) after the addition of IGF-I (50 or 100 nM) or vehicle only and treated for the last 5 h with
LPS. Data are presented as mean ± SEM and are expressed as percentage of control (vehicle + LPS) values. *,***, Significant differences (* P <
0.05; ***P < 0.001) in comparison to the values of cultures treated with vehicle + LPS.
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effect of RAd-IGF-I on IL6 mRNA levels under basal,
un-challenged conditions (Figure 8A). In fact, PPP treat-
ment increased IL6 mRNA abundance in cells infected
with the Rad-IGF-I construct or the control construct.
In contrast, PPP blocked the increase in IL-1b mRNA
levels induced by RAd-IGF-I under basal conditions
(Figure 8C). PPP also resulted in an increase in TNF-a
and TLR4 mRNA levels in cultures treated with RAd-
IGF-I (Figure 8 E,G), preventing the decrease in TLR4
mRNA levels induced by RAd-IGF-I under basal condi-
tions (Figure 8G).
In astrocytes treated with LPS, the effects of RAd-IGF-
I on IL6, IL-1b, TNF-a and TLR4 mRNA levels were
reverted by incubating the cultures for 5 h with PPP
(Figure 8B,D,F,H). In addition PPP increased mRNA
levels of IL6 and IL-1b in LPS-treated astrocytes incu-
bated with RAd-TK/GFP or RAd-IGF-I (Figure 8B,D).
RAd-IGF-I prevents LPS-induced nuclear translocation of
the NFB p65 subunit
Since activation of TLR4 results in nuclear translocation
of the NFB p65 subunit, we assessed whether RAd-
IGF-I affects p65 subcellular distribution in astrocytes.
The incubation of astrocytes with RAd-TK/GFP and
LPS resulted in a significant increase in p65 immunor-
eactivity in the cell nucleus compared to astrocytes
incubated with RAd-TK/GFP alone. In contrast, p65
nuclear immunoreactivity was not increased by LPS in
astrocytes incubated with RAd-IGF-I (Figure 9). There-
fore, RAd-IGF-I prevented LPS-induced p65 nuclear
translocation.
Discussion
The findings of the present study indicate that IGF-I
increases the expression of IL6, IL-1b and TNF-a in
cultured astrocytes under basal conditions. In contrast,
IGF-I decreases expression of IL6 and IL-1b in cultured
astrocytes submitted to a proinflammatory challenge by
treatment with LPS. Under basal conditions, the effects
of IGF-I on expression of IL6, IL-1b and TNF-a were
dependent on IGF-I dose, promoting these cytokine
expressions at the lower dose. When challenged with
LPS, however, IGF-I at both dosages exerted similar
inhibitory effects on the expression of IL6 and IL-1b.
The increases in IL6, IL-1b and TNF-a mRNA levels
detected in astrocytes after treatment with IGF-I under
basal conditions does not necessarily imply a proinflam-
matory action of IGF-I. Cytokines such as IL6, IL-1b
and TNF-a have different physiological functions,
including regulation of neuronal development, ionic
homeostasis, neuropeptide release and synaptic plasticity
[31-34]. Therefore, the observed increases in IL6, IL-1b
and TNF-a levels under basal conditions may represent
a physiological action of IGF-I. In addition, IGF-I
reduced expression of TLR4 in both the presence and
absence of LPS. TLR4 is a member of the IL-1receptor/
TLR superfamily that is expressed by astrocytes and that
is required for an LPS-induced inflammatory response
[35-38]. Therefore the observed decrease in TLR4
expression by IGF-I under basal conditions and after
LPS proinflammatory challenge may contribute to a
reduced capacity of astrocytes to be activated by proin-
flammatory molecules such as LPS. Indeed, IGF-I
reduced the effects of LPS on mRNA levels of IL6, and
IL-1b in astrocytes, in agreement with previous findings
showing that IGF-I down-regulates cytokine expression
induced by LPS in adult mouse brain [39].
Having established that exogenous IGF-I regulates the
expressions of IL6, IL-1b, TNF-a and TLR4 in astrocytes,
we then assessed whether an increase in endogenous pro-
duction of IGF-I by astrocytes might also affect expression
of these molecules. The findings of the present study indi-
cate that a recombinant adenoviral vector harboring the
gene for rat IGF-I (RAd-IGF-I) is able to increase the pro-
duction of IGF-I in astrocytes, without affecting IGFBP2
or IGF-I receptor levels. Under basal conditions, RAd-
IGF-I resulted in an effect similar to that of IGF-I, increas-
ing the expression of IL6 and IL-1b and decreasing the
expression of TLR4. Adenoviral vector infection per se
also had an effect, since mRNA levels of IL6 and IL-1b
were increased in astrocytes 72 h after incubation with
control vector, RAd-TK/GFP. In addition, TNF-a mRNA
Figure 5 RAd-IGF-I increases release of IGF-I by astrocytes.
Levels of IGF-I in the culture medium of astrocytes incubated for 24
h with medium alone (uninfected cells), RAd-TK/GFP or RAd-IGF-I.
Total IGF-I was assayed in supernatants and the peptide
concentration referred to the original volume of medium per well.
Bars on columns represent mean ± SEM, (n = 4). ***, Significant
difference (P < 0.001) versus the values of the other two
experimental groups.
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Figure 6 RAd-IGF-I increases the expression of IL6 and IL-1b and decreases the expression of TLR4 in astrocytes under basal
conditions. mRNA levels of IL6 (A,B), IL-1b (C,D), TNF-a (E,F) and TLR4 (G,H) in astrocytes 24 h (A,C,E,G) or 72 h (B,D,F,H) after the addition of
RAd-TK/GFP or RAd-IGF-I to the cultures. Data are presented as mean ± SEM and are expressed as percentage of control (uninfected cells)
values. *,**,***, Significant differences (* P < 0.05; **P < 0.01; ***P < 0.001) in comparison to the values of uninfected cells. §, §§, §§§, Significant
differences (§P < 0.05; §§P < 0.01***; §§§P < 0.001) between RAd-TK/GFP and RAd-IGF-I.
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levels were increased in astrocytes incubated for 72 h with
RAd-IGF-I. However, no increase for IL6 or IL-1b was
detected at 72 h in astrocytes infected with RAd-IGF-I,
suggesting that IGF-I is compensating for some of the
proinflammatory actions of the adenoviral vector. Indeed,
RAd-IGF-I exerted a clear anti-inflammatory action on
LPS-treated astrocytes, decreasing the mRNA levels of
IL6, IL-1b, TNF-a and TLR4. Therefore, RAd-IGF-I imi-
tated the effects of IGF-I on LPS-stimulated astrocytes.
These findings demonstrate efficacy of IGF-I gene therapy
in reducing the response of astrocytes to an inflammatory
challenge. However, as was observed for exogenous IGF-I,
the anti-inflammatory action of IGF-I gene therapy was
transient, since RAd-IGF-I did not significantly affect
levels of IL6, IL-1b, or TNF-a in cultures incubated with
the viral vector for 72 h.
Our data suggest that RAd-IGF-I, like IGF-I, reduces
the effects of LPS on astrocytes by decreasing the
Figure 7 RAd-IGF-I decreases the expression of proinflammatory molecules in LPS-stimulated astrocytes. mRNA levels of IL6 (A,B), IL-1b
(C,D), TNF-a (E,F) and TLR4 (G,H) in astrocytes 24 h (A,C,E,G) or 72 h (B,D,F,H) after the addition of RAd-TK/GFP or RAd-IGF-I and treated for the
last 5 h with LPS. Data are presented as mean ± SEM and are expressed as percentage of control (uninfected cells treated with LPS) values. *,**,
Significant differences (* P < 0.05; **P < 0.01) in comparison to the values of uninfected cells. §, §§, Significant differences (§P < 0.05; §§P < 0.01)
between RAd-TK/GFP and RAd-IGF-I.
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Figure 8 Effects of an IGF-I receptor antagonist on uninfected astrocytes and on astrocytes incubated with the adenoviral vectors.
mRNA levels of IL6 (A,B), IL-1b (C,D), TNF-a (E,F) and TLR4 (G,H) in astrocytes 24 h after the addition of RAd-TK/GFP or RAd-IGF-I and treated for
the last 5 h with the IGF-I receptor tyrosine kinase inhibitor PPP or its vehicle in the absence (A,C,E,G) or the presence of LPS (B,D,F,H). Data are
presented as mean ± SEM and are expressed as percentage of control (uninfected cells treated with the vehicle for PPP) values. *,**,***,
Significant differences (* P < 0.05; **P < 0.01; ***P < 0.001) in comparison to control values. +,++,+++, Significant differences between PPP and
its vehicle.
Bellini et al. Journal of Neuroinflammation 2011, 8:21
http://www.jneuroinflammation.com/content/8/1/21
Page 10 of 13
expression of TLR4. Activation of TLR4 results in trans-
location of the NFB p65 subunit to the cell nucleus
and consequent activation of NFB-mediated transcrip-
tion of proinflammatory cytokines and chemokines
[40-44]. In agreement with the effect of RAd-IGF-I on
TLR4 expression, and with the results of a previous
study on the effect of IGF-I on astrocytes [18], IGF-I
gene therapy prevented LPS-induced translocation of
the NFB p65 subunit to the cell nucleus. This suggests
that RAd-IGF-I exerts, at least in part, its anti-inflam-
matory action by downregulation of TLR4 and subse-
quent inhibition of NFB activity.
The anti-inflammatory action of RAd-IGF-I in LPS-
stimulated astrocytes may be mediated by IGF-I recep-
tor activation, since it was prevented by incubation of
astrocytes with cyclolignan picropodophyllin (PPP), an
inhibitor of the IGF-I receptor tyrosine phosphoryla-
tion [45-47]. However, PPP treatment per se increased
IL6 mRNA levels in cells infected with Rad-IGF-I con-
struct or control construct under basal conditions, and
increased mRNA levels of IL6 and IL-1b in LPS-trea-
ted astrocytes incubated with RAd-TK/GFP or RAd-
IGF-I. These actions of PPP cannot be explained
simply by IGF-I receptor inhibition, suggesting that
PPP may have other effects under the experimental
conditions used.
Conclusion
The results of the present study indicate that IGF-I and
IGF-I gene therapy are able to reduce inflammatory
reactions in glial cells exposed to LPS. This action of
IGF-I and IGF-I gene therapy may be relevant for con-
trol of reactive gliosis under chronic neurodegenerative
conditions, where the glial inflammatory response is
thought to have a negative impact on neuronal function
and survival.
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Figure 9 RAd-IGF-I prevents LPS-induced nuclear translocation
of the NFB p65 subunit. Astrocyte cultures were treated for 24 h
with RAd-IGF-I and for 1 h with LPS, and the level of p65
immunoreactivity in nucleus and cytoplasm was determined. A-D,
Representative examples of p65 immunostaining in astrocytes
incubated with RAd-TK/GFP (A), RAd-TK/GFP + LPS (B), RAd-IGF-I (C)
and RAd-IGF-I + LPS (D), Scale bar, 40 μm. E, Results of
densitometric analysis of p65 immunoreactivity expressed as a ratio
between immunoreactivity in the cell nucleus and the cell
cytoplasm. Data are presented as mean ± SEM and are expressed as
percentage of control (uninfected cells treated with vehicle) values.
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